Random Network Models to Predict the Long-Term Impact of HPV Vaccination on Genital Warts
Javier Díez-Domingo,
Víctor Sánchez-Alonso,
Rafael-J. Villanueva,
Luis Acedo,
José-Antonio Moraño,
Javier Villanueva-Oller
Affiliations
Javier Díez-Domingo
FISABIO-Public Health, 46020 Valencia, Spain
Víctor Sánchez-Alonso
Instituto Universitario de Matemática Multidisciplinar, 8G building, 2nd Floor, Camino de Vera, Universitat Politècnica de Valéncia, 46022 Valencia, Spain
Rafael-J. Villanueva
Instituto Universitario de Matemática Multidisciplinar, 8G building, 2nd Floor, Camino de Vera, Universitat Politècnica de Valéncia, 46022 Valencia, Spain
Luis Acedo
Instituto Universitario de Matemática Multidisciplinar, 8G building, 2nd Floor, Camino de Vera, Universitat Politècnica de Valéncia, 46022 Valencia, Spain
José-Antonio Moraño
Instituto Universitario de Matemática Multidisciplinar, 8G building, 2nd Floor, Camino de Vera, Universitat Politècnica de Valéncia, 46022 Valencia, Spain
Javier Villanueva-Oller
Departamento de Ciencias de la Computación, Arquitectura de Computadores, Lenguajes y Sistemas Informáticos, Estadística e Investigación Operativa, Universidad Rey Juan Carlos, Móstoles, 28933 Madrid, Spain
The Human papillomaviruses (HPV) vaccine induces a herd immunity effect in genital warts when a large number of the population is vaccinated. This aspect should be taken into account when devising new vaccine strategies, like vaccination at older ages or male vaccination. Therefore, it is important to develop mathematical models with good predictive capacities. We devised a sexual contact network that was calibrated to simulate the Spanish epidemiology of different HPV genotypes. Through this model, we simulated the scenario that occurred in Australia in 2007, where 12–13 year-old girls were vaccinated with a three-dose schedule of a vaccine containing genotypes 6 and 11, which protect against genital warts, and also a catch-up program in women up to 26 years of age. Vaccine coverage were 73 % in girls with three doses and with coverage rates decreasing with age until 52 % for 20–26 year-olds. A fast 59 % reduction in the genital warts diagnoses occurred in the model in the first years after the start of the program, similar to what was described in the literature.